Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results
Schiff E.
•
Lai C. -L.
•
Hadziyannis S.
altro
Metselaar H.
2007
Periodico
LIVER TRANSPLANTATION
Abstract
Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (
DOI
WOS
Archivio
Diritti
metadata only access